tirzepatide cvot SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized SURPASS-CVOT shows tirzepatide delivers comparable

Weight regain occurs in most patients after discontinuation, with approximately 50-70% of lost weight returning within 12 months

While most sexual dysfunction compounds target male physiology, PT-141s brain-based mechanism has shown relevant effects in female sexual function research as well which is part of why it achieved FDA approval for premenopausal women

Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, DSM-5

It affects metabolism, hormone function, blood sugar regulation, and long-term health

This is especially useful during the active weight-loss phase, when more frequent monitoring provides the most value

First, schedule a consultation with a licensed doctor